Tesamorelin is studied to better understand growth hormone signaling, visceral fat metabolism, and the hormonal pathways linking GH release to metabolic health.

Tesamorelin belongs to the GHRH analog peptide class and is distinguished from shorter GHRH-derived fragments — such as CJC-1295 (No DAC) — by its full 44-amino acid sequence, which preserves the complete receptor contact surface of native GHRH. Its N-terminal trans-3-hexenoic acid modification confers resistance to dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage, extending its active half-life in biological preparations without altering its receptor binding profile.

Research interest in Tesamorelin centers on its activity in the GH/IGF-1 axis and the downstream metabolic signaling consequences of sustained GHRHR activation — particularly in visceral adipose tissue biology models. In preclinical metabolic preparations, GH axis stimulation via GHRHR engagement has been associated with lipolytic signaling in visceral fat depots, IGF-1 upregulation, and insulin sensitivity pathway modulation — mechanistic areas that make Tesamorelin relevant across GH axis, adipose tissue, and metabolic signaling research.

Its well-defined receptor target, full-length sequence, and documented stability profile make it a precise and reproducible tool compound for researchers studying GHRHR pharmacology and GH-dependent metabolic pathway activity in controlled laboratory settings.

• CAS Number: 901758-09-6
• Molecular Weight: ~5196 g/mol
• Purity: ≥99%
• Also Known As: TH9507, Egrifta (pharmaceutical formulation — not supplied here), Trans-3-hexenoic acid-GHRH(1-44), GHRH analog (full-length)
• Chemical Formula: C₂₂₃H₃₇₀N₇₂O₆₉S

In cell-based and preclinical models, Tesamorelin binds to GHRHR on pituitary somatotroph preparations, activating Gs-coupled adenylyl cyclase signaling and intracellular cAMP accumulation. Downstream PKA activation drives GH granule exocytosis and somatotroph gene transcription in a pattern consistent with physiological GHRH receptor stimulation. Its N-terminal modification confers DPP-IV resistance, preserving receptor occupancy and extending the cAMP signaling window relative to unmodified GHRH in biological assay systems.

Elevated GH output in preclinical preparations subsequently stimulates hepatic IGF-1 production through GH receptor-mediated JAK2/STAT5 signaling — a well-characterized axis in GH pharmacology research. Downstream IGF-1 receptor activation engages PI3K/Akt and MAPK/ERK cascades in target tissue preparations, contributing to the anabolic and metabolic signaling consequences studied in GH axis research models.

In visceral adipose tissue preparations, GH axis activation via Tesamorelin has been associated with hormone-sensitive lipase stimulation and lipolytic signaling — mechanistically consistent with the selective visceral fat depot activity characterized in preclinical metabolic models. This adipose-selective lipolytic profile, combined with upstream GHRHR specificity, makes Tesamorelin a useful tool for dissecting GH-dependent fat metabolism signaling from broader adrenal or gonadal axis activity in metabolic research designs.

• GHRHR Binding and Receptor Pharmacology
• GH Axis Signaling and Somatotroph Biology
• IGF-1 Pathway and JAK2/STAT5 Signaling Studies
• Visceral Adipose Tissue Lipolysis Modeling
• DPP-IV Resistance and Peptide Stability Research
• Metabolic Pathway and Insulin Sensitivity Studies
• GHRH Analog Comparative Pharmacology